Survey of Drug Therapy in Type 2 Diabetes Mellitus (V). Combined Treatment with Insulin Plus an Oral Hypoglycemic Agents: Clinical Aspects and Glycemic Control (JDDM 19)

DOI Web Site 2 Citations 20 References

Bibliographic Information

Other Title
  • ２型糖尿病患者における薬物療法に関する実態調査（Ｖ）―経口血糖降下薬とインスリンの併用療法：投与薬剤と臨床像の特徴―（ＪＤＤＭ１９）
  • 2型糖尿病患者における薬物療法に関する実態調査(5)経口血糖降下薬とインスリンの併用療法:投与薬剤と臨床像の特徴(JDDM19)
  • 2ガタ トウニョウビョウ カンジャ ニ オケル ヤクブツ リョウホウ ニ カンスル ジッタイ チョウサ 5 ケイコウ ケットウ コウカヤク ト インスリン ノ ヘイヨウ リョウホウ トウヨ ヤクザイ ト リンショウゾウ ノ トクチョウ JDDM19

Search this article

Description

We have reported that, among treatment groups, glycemic control is poorest in those with Type 2 diabetes mellitus (T2DM) treated with insulin combined with an oral hypoglycemic agent (OHA). We analyzed data from 55 institutes using CoDiC®, an electronic diabetes data collection and management system, to determine the actual status of subjects treated with combination therapy. Of 43,574 T2DM cases registered in 2008, 4,684 were treated with combination therapy. Compared to T2DM subjects treated with either diet and/or OHA, onset age was younger and diabetes duration longer in those treated using combination therapy and their body mass index (BMI), HbA1c, and postprandial glycemia highest. The most commonly prescribed insulin was premixed and OHA was metformin. To determine the relationship between clinical aspects and glycemic control in these subjects, we analyzed factors affecting glycemic control stratified by HbA1c level. In those with HbA1c ≥8.0%, age and onset age were markedly lower and BMI, systolic blood pressure, and LDL-cholesterol higher than in those with HbA1c <8.0%. In Japan, T2DM subjects treated with combination therapy had the poorest glycemic control, particularly those who were younger, had earlier disease onset, and were obese.<br>

Journal

Citations (2)*help

See more

References(20)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top